Company / Net Income
Editas Medicine, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$237.1M
FY2025
5-year range
-$237.1M / -$116.0M
FY2021-FY2025
Trend
-7.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has declined for 3 consecutive years, from -$116M in FY2022 to -$237M in FY2025.
Based on SEC 10-K filings.
-$237M in FY2025.
Declined from -$193M to -$237M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Editas Medicine, Inc.'s net income has declined for 3 consecutive years.
- In FY2025, net income decreased 7.6% year-over-year.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$237.1M | -7.6% |
| FY2024 | -$220.4M | -14.5% |
| FY2023 | -$192.5M | -66.0% |
| FY2022 | -$116.0M | +13.3% |
| FY2021 | -$133.7M | -21.6% |
| FY2020 | -$110.0M | +8.6% |
| FY2019 | -$120.3M | -23.8% |
| FY2018 | -$97.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026